Walmart pumps up the fuel savings
BENTONVILLE, Ark. — Walmart is bringing Americans some much-wanted relief at the pump this fall and winter with the return of its "Great Gas Rollback" program.
Beginning Aug. 31 and ending Dec. 24, Walmart customers using a Walmart gift card will receive a 10 cent per gallon discount. Customers who use a Walmart MoneyCard or Walmart credit card will save 15 cents per gallon on their fuel purchase.
Gas will be discounted at more than 1,000 Murphy USA and Walmart gas stations located at Walmart Supercenters in participating states.
"It’s a busy time for our customers. They are sending their kids back to school and planning for Labor Day travels, and the holidays are just around the corner. As gas prices get higher, these tasks get tougher," said Duncan Mac Naughton, chief merchandising and marketing officer for Walmart U.S. "We’re here to help. Last year, we saved our customers nearly $60 million with the gas rollback program. This year, we’re excited to provide an even bigger discount on fuel that will help them save more money when they need it the most."
Abbott’s Humira gets support for expanded use
WASHINGTON — A panel of outside advisers to the Food and Drug Administration has backed wider use for Abbott Labs’ rheumatoid arthritis drug, Humira, for treating a type of inflammatory bowel disease.
According to published reports, the panel voted 15-2 that the benefits of Humira outweighed the risks in treating ulcerative colitis. However, the panel asked Abbott to conduct more studies upon Humira’s approval.
While it isn’t required to do so, the FDA typically follows panel recommendations. According to reports, a final decision is expected by the end of the year.
According to reports, the drug would only be used in people battling moderate to severe ulcerative colitis who have not had success with other medicines. If approved for ulcerative colitis, the drug maker said that Humira would be the first biologic drug that people could inject themselves.
Last November, the FDA rejected Abbott’s application for Humira in ulcerative colitis, asking for further information.
The blockbuster drug already is approved for six other conditions, including rheumatoid arthritis and Crohn’s disease.
FDA grants priority review of Zytiga sNDA
RARITAN, N.J. — The Food and Drug Administration has granted priority review to a supplemental new drug application for a drug developed by Janssen Research and Development.
Janssen Research and Development said the regulatory agency granted priority review for Zytiga (abiraterone acetate) administered in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer, who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy. Under the Prescription Drug User Fee Act, the FDA will aim to conclude its review within six months of the sNDA submission. The sNDA was submitted in June, the company said.
"We believe that men with mCRPC whose disease is asymptomatic or mildly symptomatic, for whom chemotherapy may not be immediately necessary, have limited treatment options and that this disease setting represents a critical unmet medical need," said Michael Meyers, VP and compound development team leader for Zytiga. "We are delighted the FDA has granted a priority review designation for our sNDA."